About

Jeffrey Capello has served on Agios's board since June 2023 and has been managing partner of Monomoy Advisors since April 2021.

He was previously executive vice president and chief financial officer of Biogen, and has held CFO roles at Beacon Health Options, Ortho-Clinical Diagnostics, Boston Scientific and PerkinElmer. Earlier he was a partner at PricewaterhouseCoopers. He holds an M.B.A. from Harvard Business School.

Roles

Agios Pharmaceuticals, Inc.
Director · Current role
Jun 2023–present
Biogen
EVP & Chief Financial Officer
Dec 2017 – Aug 2020
Beacon Health Options
Chief Financial Officer
Oct 2016 – Nov 2017
Ortho-Clinical Diagnostics
EVP & Chief Financial Officer
Jul 2014 – Jun 2015
Boston Scientific
EVP & Chief Financial Officer · Joined in 2008; SVP and chief accounting officer until 2010.
Mar 2010 – Dec 2013
PerkinElmer
SVP & Chief Financial Officer · Earlier VP of finance, corporate controller, treasurer and chief accounting officer (2001–2006).
2006 – 2008
PricewaterhouseCoopers
Partner · In the United States and the Netherlands.
—
Biogen Inc.
Executive Vice President and Chief Financial Officer
—

External Roles

Neogen Corporation
Director
—
Monomoy Advisors
Managing Partner
—

Director Compensation

FY 2025
Fees earned or paid in cash
$70,000
Fiscal year2025
Option awards
$299,689
Grant-date fair valueFASB ASC Topic 718
Stock awards
$99,968
Grant-date fair valueFASB ASC Topic 718
Total
$469,657

Also at Agios Pharmaceuticals, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.